An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation

• Príomhchruthaitheoirí: Mariana Floria (Údar), Alexandru Florinel Oancea (Údar), Paula Cristina Morariu (Údar), Alexandru Burlacu (Údar), Diana Elena Iov (Údar), Cristina Petronela Chiriac (Údar), Genoveva Livia Baroi (Údar), Celina Silvia Stafie (Údar), Magdalena Cuciureanu (Údar), Viorel Scripcariu (Údar), Daniela Maria Tanase (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: MDPI AG, 2024-04-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Landiolol is an ultra-short-acting, selective β1-adrenergic receptor blocker that was originally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has gained attention for its use in the management of tachyarrhythmias and perioperative tachycardia, especially atrial fibrilla...